An Early Phase 1 interventional study of Imvanex and Shingrix in Healthy, sponsored by Janssen Research & Development, LLC. Completed at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-03.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Early Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to characterize the immune response in vivo using approved vaccines and antigen challenges, as well as a skin wounding challenge to stimulate the immune system.
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive single dose of Imvanex subcutaneously on Day 1. Participants will also be included in the DREEM EEG substudy.
Biological: Imvanex
Participants will receive single dose of Shingrix intramuscularly on Day 1. Participants will also be included in the DREEM EEG substudy.
Biological: Shingrix
Participants will receive a single dose of LPS intravenously (IV) on Day 1. Participants will also be included in the DREEM EEG substudy and vital patch physIQ platform substudy.
Biological: LPS
Participants will receive one single injection of Candin and one single injection of saline control intradermally on Day 1. Participants will also be included in the DREEM EEG substudy.
Biological: Candin · Other: Saline Control
3 punch biopsies will be performed per standard dermatologic practice guidelines. Lower abdomen tissue biopsy specimens will be collected on Day 1.
Other: Skin Biopsy
Imvanex 0.5 milliliter (mL) suspension for injection will be administered as single subcutaneous (SC) injection.
Also known as: Imvamune
Shingrix 0.5 mL suspension will be administered as single intramuscular (IM) injection.
LPS 1.0 nanogram per kilogram (ng/kg) endotoxin suspension will be administered as single IV injection.
Also known as: Endotoxin
Candin 0.1 mL solution for injection will be administered as one intradermal injection.
Also known as: Candida albicans
3 punch biopsies will be performed and lower abdomen tissue biopsy specimens will be collected on Day 1.
Saline control solution for injection will be administered as one intradermal injection.
Cohort 1 and Cohort 2: Change from Baseline of Immune Cell Populations
Change from baseline in immune cell populations will be measured in peripheral blood samples or tissues of healthy volunteers.
Time frame: Baseline up to 90 days
Cohort 3 and Cohort 4: Change from Baseline of Immune Cell Populations
Change from baseline in immune cell populations will be measured in peripheral blood samples or tissues of healthy volunteers.
Time frame: Baseline up to 14 days
Cohort 5: Change from Baseline of Immune Cell Populations
Change from baseline in immune cell populations will be measured in tissues of healthy volunteers.
Time frame: Baseline up to 10 days
Cohort 1 and Cohort 2: Change from Baseline in Cell Surface Antigen Phenotype
Change from baseline in cell surface antigen phenotype will be measured in peripheral blood samples or tissues of healthy volunteers.
Time frame: Baseline up to 90 days
Cohort 3 and Cohort 4: Change from Baseline in Cell Surface Antigen Phenotype
Change from baseline in cell surface antigen phenotype will be measured in peripheral blood samples or tissues of healthy volunteers.
Time frame: Baseline up to 14 days
Cohort 5: Change from Baseline in Cell Surface Antigen Phenotype
Change from baseline in cell surface antigen phenotype will be measured in tissues of healthy volunteers.
Time frame: Baseline up to 10 days
Cohort 1 and Cohort 2: Change from Baseline in Activation Status of Inflammatory Mediators (Soluble Cytokines and Chemokines)
Soluble cytokines and chemokines will be measured by immunoassay.
Time frame: Baseline up to 90 days
Cohort 3 and Cohort 4: Change from Baseline in Activation Status of Inflammatory Mediators (Soluble Cytokines and Chemokines)
Soluble cytokines and chemokines will be measured by immunoassay.
Time frame: Baseline up to 14 days
Cohort 5: Change from Baseline in Activation Status of Inflammatory Mediators (Soluble Cytokines and Chemokines)
Soluble cytokines and chemokines will be measured by immunoassay.
Time frame: Baseline up to 10 days
Cohort 1 and Cohort 2: Change from Baseline in Activation Status of Inflammatory Mediators (Cell-bound and Tissue-associated Proteins)
Cell-bound and tissue-associated proteins will be measured by established methods including flow cytometry and immunohistochemistry.
Time frame: Baseline up to 90 days
Cohort 3 and Cohort 4: Change from Baseline in Activation Status of Inflammatory Mediators (Cell-bound and Tissue-associated Proteins)
Cell-bound and tissue-associated proteins will be measured by established methods including flow cytometry and immunohistochemistry.
Time frame: Baseline up to 14 days
Cohort 5: Change from Baseline in Activation Status of Inflammatory Mediators (Cell-bound and Tissue-associated Proteins)
Cell-bound and tissue-associated proteins will be measured by established methods including flow cytometry and immunohistochemistry.
Time frame: Baseline up to 10 days
Cohort 1 and Cohort 2: Change from Baseline in Expression of Inflammatory Mediators
Transcriptional changes in gene expression will be measured by established methods such as ribonucleic acid (RNA) microarray, RNAseq, and single cell RNA sequencing, and will be reported in number of gene transcripts per sample or per cell.
Time frame: Baseline up to 90 days
Cohort 3 and Cohort 4: Change from Baseline in Expression of Inflammatory Mediators
Transcriptional changes in gene expression will be measured by established methods such as ribonucleic acid (RNA) microarray, RNAseq, and single cell RNA sequencing, and will be reported in number of gene transcripts per sample or per cell.
Time frame: Baseline up to 14 days
Cohort 5: Change from Baseline in Expression of Inflammatory Mediators
Transcriptional changes in gene expression will be measured by established methods such as RNA microarray, RNAseq, and single cell RNA sequencing, and will be reported in number of gene transcripts per sample or per cell.
Time frame: Baseline up to 10 days
Change in Standard Deviation from Baseline of Immune Cell Populations Within a Participant
Change in standard deviation from baseline of immune cell populations within a participant will be measured.
Time frame: Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days; Cohort 5: Baseline up to 10 days
Change in Standard Deviation from Baseline of Immune Cell Populations Between Participants
Change in standard deviation from baseline of immune cell populations between participants will be measured.
Time frame: Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days; Cohort 5: Baseline up to 10 days
Change in Standard Deviation from Baseline in Cell Surface Antigen Phenotype Within a Participant
Change in standard deviation from baseline in cell surface antigen phenotype within a participant will be measured.
Time frame: Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days; Cohort 5: Baseline up to 10 days
Change in Standard Deviation from Baseline in Cell Surface Antigen Phenotype Between Participants
Change in standard deviation from baseline in cell surface antigen phenotype between participants will be measured.
Time frame: Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days; Cohort 5: Baseline up to 10 days
Change in Standard Deviation from Baseline in Activation Status of Inflammatory Mediators Within a Participant
Change in standard deviation from baseline in activation status of inflammatory mediators within a participant will be measured.
Time frame: Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days; Cohort 5: Baseline up to 10 days
Change in Standard Deviation from Baseline in Activation Status of Inflammatory Mediators Between Participants
Change in standard deviation from baseline in activation status of inflammatory mediators between participants will be measured.
Time frame: Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days; Cohort 5: Baseline up to 10 days
Change in Standard Deviation from Baseline in Expression of Inflammatory Mediators Within a Participant
Change in standard deviation from baseline in expression of inflammatory mediators within a participant will be measured.
Time frame: Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days; Cohort 5: Baseline up to 10 days
Change in Standard Deviation from Baseline in Expression of Inflammatory Mediators Between Participants
Change in standard deviation from baseline in expression of inflammatory mediators between participants will be measured.
Time frame: Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days; Cohort 5: Baseline up to 10 days
Correlation of Baseline Immune Cell Populations with Vaccine/Antigen Immune Response Phenotype
Correlation of baseline immune cell populations with vaccine/antigen immune response phenotype will be measured by phenotypic and functional assays.
Time frame: Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days
Correlation of Genomics with Vaccine/Antigen Immune Response Phenotype
Correlation of genomics with vaccine/antigen immune response phenotype will be measured by phenotypic and functional assays.
Time frame: Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days
Correlation of Serology with Vaccine/Antigen Immune Response Phenotype
Correlation of serology with vaccine/antigen immune response phenotype will be measured by phenotypic and functional assays.
Time frame: Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days
Correlation of Soluble Proteins with Vaccine/Antigen Immune Response Phenotype
Correlation of soluble proteins with vaccine/antigen immune response phenotype will be measured by phenotypic and functional assays.
Time frame: Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
No publications or documents are linked to this record.
Ran from Apr 2019 to primary completion in Dec 2019, 8 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: MVA-BN smallpox vaccine · Shingrix · Lipopolysaccharides · Candida albicans Antigen Injection
Janssen Research & Development, LLC →